Study Advocates Cautious Application of CRISPR in Designing Therapeutics
CRISPR is a powerful technology that has enabled easy disruption of desired genes and has revolutionized the field of genome editing. CRISPR-based editing has been considered for various applications in medicine, but it also has its shortcomings such as off-target effects, generation of unexpected chromosomal alterations, or potential immunogenicity.
Studies have demonstrated that DSBs induced during CRISPR-based gene knockout can lead to a DNA damage response mediated by p53, a tumor-suppressor gene that initiates programmed cell death before the cells can become cancerous. Presently it is unclear whether p53 selection can happen broadly across multiple different cell types, and whether stronger p53 selection happens when certain genes or parts of the genome are targeted.
A recent study published in Nature Communications shows that CRISPR-Cas9 based gene-editing can confer a selective advantage to cells harboring mutations in genes associated with cancer irrespective of their cell types.
Studies have demonstrated that DSBs induced during CRISPR-based gene knockout can lead to a DNA damage response mediated by p53, a tumor-suppressor gene that initiates programmed cell death before the cells can become cancerous. Presently it is unclear whether p53 selection can happen broadly across multiple different cell types, and whether stronger p53 selection happens when certain genes or parts of the genome are targeted.
A recent study published in Nature Communications shows that CRISPR-Cas9 based gene-editing can confer a selective advantage to cells harboring mutations in genes associated with cancer irrespective of their cell types.
GO Prime with only $1.49 now
LATEST
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02